64
Diamond Score
Veracyte, Inc.
Healthcare · Biotechnology · $2.7B market cap
Overlooked
Strong Foundation
$34.30
Updated 2026-04-11
Discovery Thesis
AI-generated catalyst thesis will be available after transcript analysis. The quantitative signals below highlight why this company appears to be at an inflection point.
Quantitative summary: 8Q earnings beats, PEG 0.17, deleveraging.
Three-Pillar Score Breakdown
Valuation
✦ Reasonably Priced
VCYT trades at a PEG of 0.17 — paying less than half the typical price for its growth rate.
Inflection Signals
Revenue Acceleration
4Q data
QoQ growth: -0.0351 → 0.1371 → 0.0131 → 0.0665
Margin Expansion
2Q streak
Margins: 0.0254 → -0.0405 → 0.174 → 0.1844
ROIC Trend
1.9%
0.0022 → 0.0032 → 0.0177 → 0.0192
Insider Buying
0 buys (90d)
PEG Ratio
0.17
Below 1.0 — undervalued relative to growth
Debt Paydown
D/E 0.03
0.042 → 0.041 → 0.032 → 0.03
Relative Strength (6M)
-10.7%
Earnings Surprise Streak
2026-02-25
+29.8%
$0.53 vs $0.4083
2025-11-04
+59.4%
$0.51 vs $0.32
2025-08-06
+41.9%
$0.44 vs $0.31
2025-05-07
+55.0%
$0.31 vs $0.2
Foundation — Business Quality
Revenue Growth (YoY)
16.0%
Overlooked — Why the Market Hasn't Noticed
Analyst Coverage
6 analysts
Below average
Market Cap
$2.7B
Sweet spot ($2-10B)
ETF Inclusion
Not in top ETFs